{"url_path":"/sec/rkda/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-223990-index.html","accession_number":"0001193125-26-223990","cik":"0001469443","ticker":"RKDA","issuer_name":"Arcadia Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-223990-index.html","primary_entity_key":"0001469443","primary_entity_name":"Arcadia Biosciences, Inc."},"word_count":56,"has_tables":true,"body_markdown":"ITEM 5. OTHER INFORMATION\n\nRule 10b5-1 Trading Arrangements\n\nDuring the quarter ended March 31, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.\n\n26"}